Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid β-peptide (1-42) in a transgenic Caenorhabditis elegans model

Neurobiology of Aging

Volumn 24, Issue 3, 2003, Pages 415-420

  Drake, Jennifer ^a   Link, Christopher D ^b   Butterfield, D Allan ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Amyloid beta peptide; Caenorhabditis elegans; Oxidative stress; Protein oxidation; Senile plaque

Indexed keywords

AMYLOID BETA PROTEIN; CARBONYL DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; IN VITRO STUDY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENILE PLAQUE; STATISTICAL ANALYSIS; TOXICITY; TRANSGENIC ANIMAL; WORM;

EID: 12244281810     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(02)00225-7     Document Type: Article

References (51)

1. Aksenov M.Y., Aksenova M.V., Butterfield D.A., Hensley K., Vigo-Pelfrey C., Carney J.M. Glutamine synthetase-induced enhancement of beta-amyloid peptide A beta (1-40) neurotoxicity accompanied by abrogation of fibril formation and A beta fragmentation. J. Neurochem. 66:1996;2050-2056.
2. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 42:1992;631-639.
3. Behl C., Davis J., Cole G.M., Schubert D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem. Biophys. Res. Commun. 186:1994;944-950.
4. Behl C., Davis J.B., Klier F.G., Schubert D. Amyloid beta peptide induces necrosis rather than apoptosis. Brain Res. 645:1994;253-264.
5. Braak H., Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. (Berlin). 92:1996;197-201.
6. Browne S.E., Ferrante R.J., Beal M.F. Oxidative stress in Huntington's disease. Brain Pathol. 9:1999;147-163.
7. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7:2001;548-554.
8. Butterfield D.A., Kanski J. Review: methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid β-peptide 1-42. Peptides. 23:2002;1299-1309.
9. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress(1,2). Free Radic. Biol. Med. 32:2002;1050-1060.
10. Davis D.G., Schmitt F.A., Wekstein D.R., Markesbery W.R. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol. 58:1999;376-388.
11. Davis J.N. 2nd, Chisholm J.C. The 'amyloid cascade hypothesis': decoy or real McCoy? of AD. Trends Neurosci. 20:1997;558-559.
12. Fay D.S., Fluet A., Johnson C.J., Link C.D. In vivo aggregation of beta-amyloid peptide variants. J. Neurochem. 71:1998;1616-1625.
13. Findeis M.A. Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochim. Biophys. Acta. 1502:2000;76-84.
14. Fonte V., Kapulkin V., Taft A., Fluet A., Friedman D., Link C.D. Interaction of intracellular beta-amyloid peptide with chaperone proteins. Proc. Natl. Acad. Sci. U.S.A. 99:2002;9439-9444.
15. Goldberg M.S., Lansbury P.T. Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2:2000;E115-19.
16. Gridley K.E., Green P.S., Simpkins J.W. Low concentrations of estradiol reduce beta-amyloid (25-35)-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Res. 778:1997;158-165.
17. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20:1997;154-159.
18. Harris M.E., Hensley K., Butterfield D.A., Leedle R.A., Carney J.M. Direct evidence of oxidative injury produced by theAlzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 131:1995;193-202.
19. Jarrett J.T., Berger E.P., Lansbury P.T. Jr. The carboxy terminus of the beta-amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 32:1993;4693-4697.
20. Kanski J., Aksenova M., Butterfield D.A. The hydrophobic environment of Met35 of Alzheimer's Aβ(1-42) is important for the neurotoxic and oxidative properties of the peptide. Neurotox. Res. 4:2002;219-223.
21. Kanski J., Aksenova M., Schoneich C., Butterfield D.A. Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide (1-42). Free Radic. Biol. Med. 32:2002;1205-1211.
22. Katzman R., Saitoh T. Advances in Alzheimer's disease. FASEB J. 5:1991;278-286.
23. Keller J.N., Pang Z., Geddes J.W., Begley J.G., Germeyer A., Waeg G.et al. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 69:1997;273-284.
24. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M.et al. Diffusible, non-fibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6448-6453.
25. Lansbury P.T. Jr. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc. Natl. Acad. Sci. U.S.A. 96:1999;3342-3344.
26. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G.et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 186:1990;464-478.
27. Link C.D. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 92:1995;9368-9372.
28. Link C.D., Johnson C.J., Fonte V., Paupard M., Hall D.H., Styren S.et al. Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye X-34. Neurobiol. Aging. 22:2001;217-226.
29. Link CD, Taft A, Kapulkin V, Sahagan B, Duke K, Kim S. Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. Neurobiology of Aging, in press.
30. Lorenzo A., Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. U.S.A. 91:1994;12243-12247.
31. Mango S.E. Stop making non-sense: the C. elegans smg genes. Trends Genet. 17:2001;646-653.
32. Mark R.J., Lovell M.A., Markesbery W.R., Uchida K., Mattson M.P. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J. Neurochem. 68:1997;255-264.
33. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23:1997;134-147.
34. Obrenovich ME, Joseph JA, Atwood CS, Perry G, Smith MA. Amyloid-β: a (life) preserver for the brain. Neurobiol Aging, in press.
35. Oda T., Wals P., Osterburg H.H., Johnson S.A., Pasinetti G.M., Morgan T.E.et al. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp. Neurol. 136:1995;22-31.
36. Pike C.J., Walencewicz-Wasserman A.J., Kosmoski J., Cribbs D.H., Glabe C.G., Cotman C.W. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem. 64:1995;253-265.
37. Roses A.D. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J. Neuropathol. Exp. Neurol. 53:1994;429-437.
38. Samuel W., Terry R.D., DeTeresa R., Butters N., Masliah E. Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. Arch. Neurol. 51:1994;772-778.
39. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T.et al. Immunization with amyloid beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
40. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N.et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:1996;864-870.
41. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:2001;741-766.
42. Snyder S.W., Ladror U.S., Wade W.S., Wang G.T., Barrett L.W., Matayoshi E.D.et al. Amyloid beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 67:1994;1216-1228.
43. Suzuki N., Cheung T.T., Cai X.D., Odaka A., Otvos L. Jr., Eckman C.et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 264:1994;1336-1340.
44. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R.et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30:1991;572-580.
45. Varadarajan S., Kanski J., Aksenova M., Lauderback C., Butterfield D.A. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1-42) and A beta(25-35). J. Am. Chem. Soc. 123:2001;5625-5631.
46. Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130:2000;184-208.
47. Varadarajan S., Yatin S., Butterfield D.A. Alzheimer's amyloid β peptide (1-42) fibrils are not always neurotoxic. Alz. Rep. 3:2000;71-76.
48. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A.et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274:1999;45-52.
49. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S.et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:2002;535-539.
50. Yatin S., Varadarajan S., Butterfield D.A. Vitamin E prevents Alzheimer's amyloid β-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. J. Alz. Dis. 2:2000;123-131.
51. Yatin S.M., Varadarajan S., Link C.D., Butterfield D.A. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol. Aging. 20:1999;325-330.